TY - JOUR
T1 - Targeted endometrial cancer therapy as a future prospect
AU - Thanapprapasr, Duangmani
AU - Cheewakriangkrai, Chalong
AU - Likittanasombut, Puchong
AU - Thanapprapasr, Kamolrat
AU - Mutch, David G.
PY - 2013/3
Y1 - 2013/3
N2 - Among female-specific cancers worldwide, endometrial cancer is the third most common after breast cancer and cervical cancer. In addition, it is the most common gynecological cancer in the USA and Europe. The incidence of this disease appears to be increasing. The cause of this increase is multifactorial, but a few possible factors involved are increasing obesity, an aging population leading to more postmenopausal women and greater tamoxifen use. Surgery is generally the primary treatment of this disease and postoperative radiation therapy in some patients with high or intermediate risk may prevent locoregional recurrences. Adjuvant chemotherapy improves progression-free survival in advanced or recurrent cancer. However, overall survival in patients with advanced disease is poor. Hence, better therapy is needed and targeted molecular therapies are emerging as possible treatment candidates. These include molecules that target VEGF, mTOR, tyrosine kinases, human EGF receptors and FGF receptors. Therapies targeting specific molecular features should be evaluated in future strategies in the treatment of endometrial cancer.
AB - Among female-specific cancers worldwide, endometrial cancer is the third most common after breast cancer and cervical cancer. In addition, it is the most common gynecological cancer in the USA and Europe. The incidence of this disease appears to be increasing. The cause of this increase is multifactorial, but a few possible factors involved are increasing obesity, an aging population leading to more postmenopausal women and greater tamoxifen use. Surgery is generally the primary treatment of this disease and postoperative radiation therapy in some patients with high or intermediate risk may prevent locoregional recurrences. Adjuvant chemotherapy improves progression-free survival in advanced or recurrent cancer. However, overall survival in patients with advanced disease is poor. Hence, better therapy is needed and targeted molecular therapies are emerging as possible treatment candidates. These include molecules that target VEGF, mTOR, tyrosine kinases, human EGF receptors and FGF receptors. Therapies targeting specific molecular features should be evaluated in future strategies in the treatment of endometrial cancer.
KW - endometrial cancer
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84874892992&partnerID=8YFLogxK
U2 - 10.2217/whe.13.4
DO - 10.2217/whe.13.4
M3 - Review article
C2 - 23477324
AN - SCOPUS:84874892992
SN - 1745-5057
VL - 9
SP - 189
EP - 199
JO - Women's Health
JF - Women's Health
IS - 2
ER -